Centrexion President and Chief Scientific Officer Dr. James Campbell will present during the GBC Bioscience Committee meeting at 8:15 a.m. Thursday, July 24.
Centrexion is a Baltimore biotech company launched late 2013, which has raised $23.4 million in funds for its products, according to the Baltimore Business Journal.
Campbell is the founder and CEO of Canton biotech company Arcion, which developed a topical gel to treat chronic pain. Additionally, he is professor of neurological surgery at Johns Hopkins School of Medicine and director of Hopkins’ Blaustein Pain Treatment Center.
For more information about the GBC Bioscience Committee, contact Liz Pettengill at email@example.com or 410-727-2820.